Cytocom, Inc.

CYTOCOM

Pharmaceutical preparations and compounds for the prevention and treatment of Crohn's disease, multiple sclerosis, viral infections, lipodystrophy syndrome, HIV/AIDS, cancer, cell growth related disorders, cell proliferation related disorders, inflammatory diseases, ulcerative diseases, autoimmune diseases, autism, Parkinson's disease and lymphoproliferative syndrome; pharmaceutical preparations and compounds for reducing side effects in cancer treatment; pharmaceutical preparations and compounds for stimulating the immune system in an immunocompromised patient;Chemical compounds for use as an adjuvant in the manufacture of pharmaceutical preparations;

CYTOCOM

Educational services, namely, conducting classes, seminars, conferences, and workshops in the medical, pharmaceutical, and healthcare fields and distributing printed course materials in conjunction therewith; providing online journals, namely, blogs in the medical, pharmaceutical and health fields;Pharmaceutical preparations and compounds for use in immune modulation, oncology, infectious diseases; pharmaceutical preparations for the treatment or prevention of immune-mediated diseases, Crohn's disease, multiple sclerosis, viral infections, HIV/AIDS, cancer, cell growth related disorders, cell proliferation related disorders, inflammatory diseases, ulcerative diseases, autoimmune diseases, autism, dermatological, cardiovascular, hematological, bone, respiratory, central nervous system, endocrinological, circulatory, gastroenterological, stomach, digestive, hormonal, diabetic, muscular, rheumatic, immune system, ocular and metabolic diseases and disorders; anti-infectives; anti-inflammatories; vaccines; pharmaceutical preparations and compounds for reducing side effects in cancer treatment; pharmaceutical preparations and compounds for stimulating the immune system in an immunocompromised patient; dietetic substances for medical purposes, namely, nutritional, vitamin and mineral supplements;Medical and pharmaceutical research services; pharmaceutical research and development;

CYTOCOM BIOSCIENCES

Pharmaceutical preparations and compounds for the prevention and treatment of Crohn's disease, multiple sclerosis, viral infections, lipodystrophy syndrome, HIV/AIDS, cancer, cell growth related disorders, cell proliferation related disorders, inflammatory diseases, ulcerative diseases, autoimmune diseases, autism, Parkinson's disease and lymphoproliferative syndrome; pharmaceutical preparations and compounds for reducing side effects in cancer treatment; pharmaceutical preparations and compounds for stimulating the immune system in an immunocompromised patient;Chemical compounds for use as an adjuvant in the manufacture of pharmaceutical preparations;BIOSCIENCES;

LOTREXON

Pharmaceutical preparations and substances that are used alone or in combination with other pharmaceuticals, preparations or substances, and that act on the nervous system; pharmaceutical preparations and substances that that are used alone or in combination with other pharmaceuticals, preparations or substances, and have immunomodulatory activity; pharmaceutical preparations and substances that that are used alone or in combination with other pharmaceuticals, preparations or substances, and have anti-inflammatory activity; pharmaceutical preparations and substances that that are used alone or in combination with other pharmaceuticals, preparations or substances, and have hematopoietic lineage differentiation activity; pharmaceutical preparations and substances that are used alone or in combination with other pharmaceuticals, preparations or substances, and that act on various G protein-coupled receptors; pharmaceutical preparations and substances that are used alone or in combination with other pharmaceuticals, preparations or substances, and that act on non-GPCRs, including Toll-like receptors and p receptors; pharmaceutical preparations and substances that are used alone or in combination with other pharmaceuticals, preparations or substances, for the prevention and treatment of gastrointestinal, neurological, immunological, oncological and/or viral diseases and disorders;

STATERA BIOPHARMA

The mark consists of eight round dots of two different sizes forming the overall appearance of a diamond shape. Two of the dots are connected by a line. Below the diamond shape are the words STATERA BIOPHARMA, with the letter A stylized. The word STATERA appears in larger font than the word BIOPHARMA. BIOPHARMA appears underneath STATERA.;Pharmaceutical preparations and compounds for use in immune modulation, oncology, infectious diseases; pharmaceutical preparations for the treatment or prevention of immune-mediated diseases, Crohn's disease, multiple sclerosis, viral infections, HIV/AIDS, cancer, cell growth related disorders, cell proliferation related disorders, inflammatory diseases, ulcerative diseases, autoimmune diseases, autism, dermatological, cardiovascular, hematological, bone, respiratory, central nervous system, endocrinological, circulatory, gastroenterological, stomach, digestive, hormonal, diabetic, muscular, rheumatic, immune system, ocular and metabolic diseases and disorders; anti-infectives; anti-inflammatories; vaccines; pharmaceutical preparations and compounds for reducing side effects in cancer treatment; pharmaceutical preparations and compounds for stimulating the immune system in an immuno-compromised patient; dietetic substances for medical purposes, namely, nutritional, vitamin and mineral supplements;Medical and pharmaceutical research services; pharmaceutical research and development;